Literature DB >> 12804866

Structure-dependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines.

Jorge L Martinez-Torrecuadrada1, Narciís Saubi, Albert Pagès-Manté, José R Castón, Enric Espuña, J Ignacio Casal.   

Abstract

The immunogenicity and protective capability of several baculovirus-expressed infectious bursal disease virus (IBDV)-derived assemblies as VP2 capsids, VPX tubules and polyprotein (PP)-derived mixed structures, were tested. Four-week-old chickens were immunised subcutaneously with one dose of each particulate antigen. VP2 icosahedral capsids induced the highest neutralising response, followed by PP-derived structures and then VPX tubules. All vaccinated animals were protected when challenged with a very virulent IBDV (vvIBDV) isolate, however the degree of protection is directly correlated with the levels of neutralising antibodies. VP2 capsids elicited stronger protective immunity than tubular structures and 3 micrograms of them were sufficient to confer a total protection comparable to that induced by an inactivated vaccine. Therefore, VP2 capsids represent a suitable candidate recombinant vaccine instead of virus-like particles (VLPs) for IBDV infections. Our results also provide clear evidence that the recombinant IBDV-derived antigens are structure-dependent in order to be efficient as vaccine components.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804866     DOI: 10.1016/s0264-410x(02)00804-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Ability of Lactococcus lactis to export viral capsid antigens: a crucial step for development of live vaccines.

Authors:  Yakhya Dieye; Arjan J W Hoekman; Florence Clier; Vincent Juillard; Hein J Boot; Jean-Christophe Piard
Journal:  Appl Environ Microbiol       Date:  2003-12       Impact factor: 4.792

2.  Overexpression of recombinant infectious bursal disease virus (IBDV) capsid protein VP2 in the middle silk gland of transgenic silkworm.

Authors:  Hanfu Xu; Lin Yuan; Feng Wang; Yuancheng Wang; Riyuan Wang; Chunnuan Song; Qingyou Xia; Ping Zhao
Journal:  Transgenic Res       Date:  2014-08-09       Impact factor: 2.788

3.  Efficacy of VP2 protein expressed in E. coli for protection against highly virulent infectious bursal disease virus.

Authors:  Abdul Rahman Omar; Chong Lee Kim; Mohd Hair Bejo; Aini Ideris
Journal:  J Vet Sci       Date:  2006-09       Impact factor: 1.672

4.  Chimeric calicivirus-like particles elicit specific immune responses in pigs.

Authors:  E Crisci; L Fraile; N Moreno; E Blanco; R Cabezón; C Costa; T Mussá; M Baratelli; P Martinez-Orellana; L Ganges; J Martínez; J Bárcena; M Montoya
Journal:  Vaccine       Date:  2012-02-03       Impact factor: 3.641

5.  Development of diagnostic tools for IBDV detection using plants as bioreactors.

Authors:  Evangelina Gómez; María Florencia Cassani; María Soledad Lucero; Viviana Parreño; Silvina Chimeno Zoth; Analía Berinstein
Journal:  AMB Express       Date:  2020-05-20       Impact factor: 3.298

Review 6.  Vaccines for viral and parasitic diseases produced with baculovirus vectors.

Authors:  Monique M van Oers
Journal:  Adv Virus Res       Date:  2006       Impact factor: 9.937

7.  Protective oral vaccination against infectious bursal disease virus using the major viral antigenic protein VP2 produced in Pichia pastoris.

Authors:  Omid Taghavian; Holger Spiegel; Rüdiger Hauck; Hafez M Hafez; Rainer Fischer; Stefan Schillberg
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

Review 8.  Subviral particle as vaccine and vaccine platform.

Authors:  Ming Tan; Xi Jiang
Journal:  Curr Opin Virol       Date:  2014-03-21       Impact factor: 7.090

9.  Infectious bursal disease virus in chickens: prevalence, impact, and management strategies.

Authors:  Sohini Dey; Dinesh C Pathak; Narayan Ramamurthy; Hemanta Kumar Maity; Madhan Mohan Chellappa
Journal:  Vet Med (Auckl)       Date:  2019-08-05

Review 10.  Virus-like particles as a vaccine delivery system: myths and facts.

Authors:  Polly Roy; Rob Noad
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.